瑞扎芬净治疗侵袭性念珠菌病和/或念珠菌血症患者的住院和重症监护室停留时间:两项随机对照试验的汇总分析
本文为ReSTORE(NCT03667690)和STRIVE(NCT02734862)两项随机对照试验的事后汇总探索性分析,比较瑞扎芬净与每日静脉注射卡泊芬净治疗侵袭性念珠菌病/念珠菌血症的住院和ICU停留时间。汇总改良意向治疗人群共294例(瑞扎芬净139例,卡泊芬净155例),43%(126例)有ICU入住。瑞扎芬净组总住院时间平均25.2天 vs 卡泊芬净组28.3天,ICU停留时间平均16.1天 vs 21.6天;校正机械通气状态后ICU停留时间差异为4.1天,相对差异24%(95%CI -11%, 72%)。医生认为16%(30/187)的患者使用每周瑞扎芬净可提前出院,平均提前5-6天。作者认为瑞扎芬净可能缩短住院和ICU停留时间并节省资源,但需在真实世界环境中进一步研究确认。
要点
- 汇总mITT人群294例(瑞扎芬净139例,卡泊芬净155例),43%(126例)有ICU入住。
- 瑞扎芬净组总住院时间平均25.2天 vs 卡泊芬净组28.3天。
- 瑞扎芬净组ICU停留时间平均16.1天 vs 卡泊芬净组21.6天。
- 校正机械通气状态后ICU停留时间差异为4.1天,相对差异24%(95%CI -11%, 72%),未达统计学显著。
- 医生认为16%(30/187)的患者使用每周瑞扎芬净可提前出院,平均提前5-6天。
适用人群与场景
- 汇总改良意向治疗人群:所有在试验要求下记录有念珠菌感染并接受至少一剂研究药物的患者,共294例(瑞扎芬净139例,卡泊芬净155例),其中126例(43%)有ICU入住。
处置流程与药物剂量
- 瑞扎芬净为每周一次静脉注射棘白菌素;卡泊芬净为每日静脉注射,卡泊芬净组病情稳定且符合相关标准的患者可在3天或更长时间后降阶梯为氟康唑。
研究设计与关键结果
- 研究类型:两项随机对照试验(ReSTORE和STRIVE)的事后汇总探索性分析;样本量294例(瑞扎芬净139例,卡泊芬净155例);人群为侵袭性念珠菌病/念珠菌血症患者;干预为瑞扎芬净 vs 每日静脉注射卡泊芬净。
- 主要终点结果:瑞扎芬净组总住院时间平均25.2天 vs 卡泊芬净组28.3天;瑞扎芬净组ICU停留时间平均16.1天 vs 卡泊芬净组21.6天。
- 校正机械通气状态后ICU停留时间差异为4.1天,相对差异24%(95%CI -11%, 72%)。
- 医生认为16%(30/187)的患者使用每周瑞扎芬净可提前出院,平均提前5-6天。
证据类型、等级与局限
- 证据类型:两项随机对照试验的事后汇总探索性分析(post hoc pooled exploratory analysis)。
- 局限:原文报告需在真实世界环境中进一步研究确认。
对床旁实践的改变
- 作者认为,与每日静脉注射卡泊芬净相比,瑞扎芬净可能缩短侵袭性念珠菌病/念珠菌血症患者的住院和ICU停留时间,并伴随资源利用的节省。
- 原文结论指出需在真实世界环境中进一步研究确认。
指南或共识出处
- ReSTORE(NCT03667690,2018年9月12日);STRIVE(NCT02734862,2016年4月12日)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay. The once-weekly IV echinocandin, rezafungin acetate, has demonstrated non-inferiority to caspofungin in the treatment of IC/C. This paper reports a post hoc pooled exploratory analysis of length of stay (LoS) for hospital and intensive care unit (ICU) stays in two previously published clinical trials (ReSTORE [NCT03667690] and STRIVE [NCT02734862], that compared rezafungin with daily IV caspofungin (stable patients in the caspofungin group who met relevant criteria could step down to fluconazole after 3 days or more).
METHODS: LoS outcomes were analysed descriptively in the pooled modified intention to treat (mITT) population (all patients who had a documented Candida infection in line with trial requirements and received at least one dose of study drug). In addition, to adjust for an imbalance between treatment groups in the proportion receiving mechanical ventilation at baseline, a generalised linear model with mechanical ventilation as a binary covariate was applied. Responses to an exploratory question in the phase 3 trial on possible earlier discharge with weekly rezafungin are also reported.
RESULTS: 294 patients were included (rezafungin 139, caspofungin 155), of whom 126 (43%) had ICU admission. Patients treated with rezafungin had a numerically shorter LoS than with caspofungin in all analyses. Mean total LoS was 25.2 days, vs 28.3 days with caspofungin, and mean ICU LoS was 16.1 vs 21.6 days for rezafungin and caspofungin, respectively. After adjustment for mechanical ventilation status the difference in ICU LoS was 4.1 days, a relative difference of 24% (95% CI -11%, 72%). Physicians would have considered earlier discharge for 16% of patients (30/187) with weekly rezafungin, an average of 5-6 days earlier.
CONCLUSIONS: Rezafungin may enable shorter hospital and ICU LoS in IC/C compared with daily IV caspofungin, with accompanying savings in resource use. Further research is needed to confirm this in the real-world setting.
TRIAL REGISTRATION: NCT03667690 (ReSTORE; September 12, 2018); NCT02734862 (STRIVE; April 12, 2016).
参考来源
- Honoré PM, Bassetti M, Cornely OA, et al. Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. Crit Care. 2024. PMID: 39529079. doi:10.1186/s13054-024-05152-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。